Immunitrack ApS and Intavis Peptide Services help identifying SARS-CoV-2 / hCoV19 Spike T-Cell Epitopes.
We are happy and proud to announce that Immunitrack ApS in cooperation with Intavis Peptide Services have accomplished an outstanding achievement
in the fight against the global pandemic.
Utilizing the unparalleled ability of Intavis Peptide Services to deliver up to 1536 peptides in a 14 day time-frame,
Immunitrack were able to identify the 96 most promising SARS-CoV-2 / hCoV19 Spike protein peptide candidates for vaccine development.
To accommodate the need for rapid vaccine development and to understand patient immune responses, Immunitrack offers two Spike T cell epitope kits, which may be used to stimulate antigen-specific T cells in assays such as ELISpot, intracellular cytokine staining assays, and cytotoxicity or proliferation assays.
These products are the result of a collaboration between Intavis and Immunitrack and may be ordered by contacting Immunitrack.
Each kit consists of 96 SARS-CoV-2 Spike peptides validated in in vitro stability binding assays to one or more frequent HLA alleles. The kit comes with a report containing the binding assay data.
Read the full report here.